Skip to main content
EJNMMI Research
Fig. 1 | EJNMMI Research

Fig. 1

From: The use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor

Fig. 1

A single dose of AZD8186 (50 mg/kg) shows tumour growth inhibition in PTEN mutated models of cancer with selectivity against PI3Kα. Tumour volume following AZD8186 dosing (mean ± SEM). a 786-0: vehicle n = 10; AZD8186 n = 10. b U87-MG: vehicle n = 12; AZD8186 n = 9. c BT474C: vehicle n = 12; AZD87186 n = 9. *p < 0.05 unpaired t test

Back to article page